MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Exclusion Criteria

• •Uncontrolled or current infection
• •Known standard therapy for the patient's disease that is potentially curative or proven capable of extending life expectancy
• •Known allergy to any of the vaccine or adjuvant components, including eggs
• •Any of the following prior therapies with interval since most recent treatment:
• •* Chemotherapy =\< 4 weeks prior to registration
• •* Biologic or immunologic therapy =\< 4 weeks prior to registration
• •* Radiation therapy =\< 4 weeks prior to registration
• •Failure to fully recover from side effects of prior therapy or surgery
• •Any of the following:
• •* Pregnant women
• •* Nursing women
• •* Women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.)
• •Known immune deficiency, including human immunodeficiency virus (HIV) infection
• •History of systemic autoimmune disease, as patients with ongoing autoimmunity may be at an increased risk of autoimmune toxicity from the study vaccine
• •Current or recent (=\< 4 weeks) use of immunosuppressive medications including systemic (inhaled, oral, or intravenous \[IV\]) corticosteroids; Note: use of corticosteroids in doses not exceeding those used for adrenal replacement is acceptable
• •History of brain metastases; EXCEPTION: patients with a solitary brain metastasis that has been completely resected, and who have no ongoing central nervous system (CNS) symptoms and an MRI documenting no evidence of CNS disease at least 3 months after resection and within 30 days of registration, are eligible for treatment
• •Other active malignancy =\< 5 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history of prior malignancy \> 5 years prior to registration, the patient must not be receiving other cancer treatment